Abcam, ab303613, Anti-Glucokinase antibody [EPR25847-150] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal HXK4 antibody. Carrier free. Suitable for IHC-P and reacts with Human, Mouse samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR25847-150,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human, Mouse,
Applications:IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Glucokinase also known as GCK is an enzyme with a mass around 50 kDa. It functions by catalyzing the phosphorylation of glucose to glucose-6-phosphate an important step in glycolysis. Glucokinase displays a higher affinity for glucose as compared to other hexokinases which is indicated by its specific kinetic property known as the Km value. This enzyme is mainly expressed in the liver and pancreatic beta-cells where it plays an important role in glucose metabolism. Additionally glucokinase can also be found in the hypothalamus indicating its broader reach in carbohydrate sensing.
Biological function summary
Glucokinase acts as a glucose sensor regulating blood sugar levels and insulin secretion. This process does not involve the enzyme as part of a larger complex. Instead glucokinase functions independently to sense glucose concentrations and adjusts the rate of glucose phosphorylation accordingly. Its activity significantly affects the balance of glucose uptake and energy production especially during postprandial states when glucose levels rise. Glucokinase activity is therefore important to maintaining glucose homeostasis.
Pathways
Glucokinase plays a central role in the glycolytic pathway and interacts with the insulin signaling pathway. Within these pathways it influences how the liver stores glucose as glycogen and controls insulin release from pancreatic beta-cells. Glucokinase activity is modulated by glucose levels and is closely related to insulin receptor substrates that affect downstream insulin signaling. Its function is important for the proper regulation of these pathways linking glucose sensing with metabolic control in varied tissues.
Glucokinase is pivotal in the context of diabetes mellitus and hyperglycemia. Mutations or dysregulation of glucokinase can lead to different forms of diabetes including maturity-onset diabetes of the young type 2 (MODY2). Glucokinase inhibitors and activators are being explored as potential therapeutic agents for modulating glucose levels in diabetics. Additionally its role interfaces with the functions of insulin tying glucokinase closely to conditions of insulin resistance and pancreatic dysfunction. Understanding these connections is instrumental for developing targeted treatment strategies.